ASH 2024 – Jaypirca's confirmation, despite no survival
Crossover scuppers Jaypirca's survival benefit, but full approval seems likely.
ASH 2024 – AstraZeneca aims to fix Calquence’s position
But with Brukinsa and degraders looming, will fixed dosing make the difference?
FDA red and green lights: November 2024
Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.
The month ahead: December’s upcoming events
Party season approaches; but first, conferences.
Genmab formalises the challenge against its partner
GEN1286/PRO1286 features among the latest industry projects to enter clinical trials.
ASH 2024 preview – more challenges to the BTK order
First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.
BeiGene tries where others failed
The company’s CEACAM5 and PRMT5 projects feature among the latest first-in-human entrants.
KRAS strikes back
First-in-human trial initiations reveal four KRAS assets.
PD-1 drugs set to have their stomach cancer wings clipped
A US adcom strongly recommends restricting Keytruda, Opdivo and Tevimbra use to PD-L1 expressers.
